BIT Charting, page-618

This exert from the letter to shareholders October 2018:
In coming weeks, Biotron will brief potential
pharmaceutical partners on the trial outcomes. We
believe that the successful results from this study will
facilitate commercialisation negotiations with these
parties.

And this from the letter to shareholders September 2023:
Biotron expects to have data from three such
trials available in the very near term which puts
the Company in a very strong position. These
data, if positive, will be central to successfully
negotiating and completing a commercial
transaction for the Company’s HIV‐1 and
COVID‐19 clinical programs.

Good luck to us all!!